This may affect the recruitment of immune cells, including the CD103+ DCs or classical type 1 DCs (cDC1s), which excel in priming and cross-presentation of tumor antigens to CD8+ T cells, and CD11b+ DCs or cDC2s, which are more potent at driving CD4+ helper T cell responses.28 The gene discussed is ITGAE; the disease is neoplasm.